AstraZeneca Announced Enhertu Approved In China For Patients With Previously Treated HER2-Positive Advanced Or Metastatic Gastric Cancer
Author: Benzinga Newsdesk | August 13, 2024 05:20am
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior treatment regimens.
Posted In: AZN FXI